Refine by
Biomaterials Articles & Analysis: Older
89 news found
Nokian Tyres has signed a development agreement with a Swedish biomaterial science company Reselo AB to further develop their renewable material Reselo Rubber as a potential new raw material in tyres Reselo Rubber is a completely renewable material made from birch bark sourced from the residue of the global pulp, paper and plywood industry. ...
Owing to the advances of modern synthetic polymer chemistry, varieties of functional polymers have been developed for various applications including optoelectronics, catalysis, biomaterials, medicine, building materials, water treatment, coatings, and many more. ...
In the field of regenerative medicine and tissue engineering, the demand for collagen-based biomaterials is rapidly increasing. Collagen, the most abundant protein in the human body, plays a crucial role in maintaining the structure and function of various tissues. ...
CD Bioparticles can provide customers with a wide range of functional groups/targeting ligands/tags covering polymers for loading, modification, specific targeting, tracking and detection, as well as functional groups in different densities or different chemical geometries to fabricate biomaterials with controllable functionality and other physical/chemical properties (e.g. ...
Featured Bio-ink products at Matexcel include Basic Photocurable Biomaterials GelMA, 300g Bloom, 81-100%, GelMA, 300g Bloom, 61-80%, GelMA, 300g Bloom, 41-60%, GelMA, 300g Bloom, <40%, HAMA, Mw400-900kDa, 31-50%, Chondroitin Sulphate Methacrylate (CSMA), Alginate Methacrylate (ALMA), Methacrylated Carboxymethyl Chitosan (CMCSMA), Methacrylated Silk Fibroin (SFMA), etc. ...
ByMatexcel
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. ...
ByCELLINK
Shaochen Chen leads the field for cutting-edge research in 3D bioprinting and biomaterials for tissue engineering and regenerative medicine applications. The group not only investigates the fundamental scientific issues, such as cell interactions with micro and nano-environments, biomaterials science, and biomechanics, but also solves the technological and ...
ByCELLINK
The field was then at an early stage of development and reimbursement for basic embolization beads was insufficient to justify the expensive clinical trials required for a new biomaterial-based solution. That’s not the case today. “There are existing codes that provide adequate reimbursement, and that makes this attractive from the standpoint of commercial ...
This experiment will examine the biomaterial's osteoconductivity when used in a microgravity environment where bone density and the ability to regenerate new bone tissue is significantly compromised. ...
LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. The clinical use of this ...
“The adhesive and structural features of this biomaterial combined with the fact that it is osteoconductive and ultimately replaced by bone make it an excellent candidate for an improved vertebroplasty procedure,” said Dr. ...
“Since initiating the prior MHRA-approved study in the United Kingdom, RevBio has significantly improved the osteopromotive potential of its biomaterial.” RevBio has optimized its bone adhesive biomaterial primarily by adjusting the pH of the material as it undergoes its self-setting reaction. ...
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre ...
In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable ...
It focused its search in healthcare and the life sciences, including development platforms that enable applications in prevention, diagnosis, treatment, or advanced biomaterials and, within that context, life-sciences tools, enabling software, synthetic biology and novel drug ...
In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. ...
In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. ...
“We are pleased to broaden the scope of our agreement with Advanced BioMatrix and the opportunity to include the commercial supply of clinical-grade HyStem as part of ABM’s biomaterials & bioprinting portfolio which is widely available to the cell therapy product development community,” stated Brian M. ...
It can provide drug-delivery cargos with controllable delivery profile, or active biomaterials with various of ready-to-use bio-conjugation options, and hydrogels with sol-gel transition useful for reversible encapsulation and delivery. ...
In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. ...